Apimeds Pharmaceuticals (APUS) said late Thursday it priced its initial public offering at $4 per share, offering 3.4 million shares for $13.5 million in gross proceeds.

The company said the shares would begin trading Friday on the NYSE under the ticker symbol 'APUS.'

Additionally, the company also said it granted underwriters a 45-day option to buy 506,250 more shares and issued warrants for up to 194,063 shares.

Proceeds will fund a phase III knee osteoarthritis trial, MS study, product manufacturing, and general operations, the company said, adding the offering is expected to close Monday.